UU Innovation

Funding from EIT Health shortens time to market


Four questions to Ingrid Carlbom, Professor Emeritus at the Department of Information Technology and one of the founders of CADESS Medical AB.

Ingrid Carlbom. Photo: Mikael Wallerstedt.

CADESS Medical develops a decision support system that helps physicians determine who can live with prostate cancer and who requires aggressive treatment to survive. At the end of 2017, the company received 37.500 € from EIT Health to accelerate market entry.

How does the system work?
– CADESS™ takes as input digitized images of biopsy tissue and identifies the cancer malignancy grade on a glandular level. CADESS guides the pathologist to an accurate, reproducible, and quantitative identification of the malignant glands in the prostate.

Why prostate cancer?
– Prostate cancer is the leading cause of cancer-deaths in men in the US as well as many other countries, and the CDC (Centers for Disease Control and Prevention) expect it to become the leading cause of death in men, surpassing heart disease, by 2020. It is one of the hardest cancers to evaluate, with a 30-40 percent inter- and intra-observer variation even among the most experienced pathologists.

What are the benefits of CADESS?
– Reduced needless suffering by avoiding treatment that does not prolong life. It also has the potential to reduce the healthcare costs – in the US by about as much as 500 million dollars yearly.

What impact does the funding from EIT Health have on your company?
– It will allow us to plan a multi-center, multi-national validation study, which is a requirement for seeking regulatory approval.